Investment Thesis
Revolution Medicines is a pre-revenue clinical-stage biotech company with an unsustainable cash burn rate of $913.7M annually against cash reserves of only $383.7M, implying sub-5-month runway. The company reported $1.2B in operating losses and $1.1B net losses with deteriorating EPS (-66.2% YoY), indicating worsening financial trajectory and likely need for dilutive capital raises or major clinical/commercial milestones to survive.
Strengths
- Zero debt with Debt/Equity ratio of 0.00x providing financial flexibility
- Strong liquidity position with Current Ratio of 7.14x and $383.7M in cash equivalents
- Favorable stockholders equity of $1.6B relative to $723.2M liabilities showing negative debt burden
Risks
- Pre-revenue company with $0.00 revenue and no commercial-stage products generating sales
- Catastrophic cash burn of $913.7M annually against $383.7M cash reserves represents critical runway crisis (<5 months at current burn)
- Severely deteriorating profitability with EPS declining 66.2% YoY and operating losses exceeding $1.2B annually
- Dependent on successful clinical trial outcomes or capital markets access to avoid insolvency
Key Metrics to Watch
- Quarterly operating cash flow burn rate and cash runway remaining
- Pipeline clinical trial progress and regulatory milestones
- Equity dilution from any capital raises and their timing relative to cash depletion
Financial Metrics
Revenue
0.0
Net Income
-1.1B
EPS (Diluted)
$-5.95
Free Cash Flow
-913.7M
Total Assets
2.4B
Cash
383.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-69.3%
ROA
-48.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
7.14x
Quick Ratio
7.14x
Debt/Equity
0.00x
Debt/Assets
30.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T05:06:22.647995 |
Data as of: 2025-12-31 |
Powered by Claude AI